Grünenthal acquires testosterone treatment Nebido™ from Bayer ...Middle East

Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal's EBITDA in 2023. NebidoTM is the gold standard for the treatment of male hypogonadism associated with testosterone deficiency. It is available to patients...

Hence then, the article about grunenthal acquires testosterone treatment nebido from bayer was published today ( Thursday 14/07/2022 - 11:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Grünenthal acquires testosterone treatment Nebido™ from Bayer )

Also on site :

• AI companies are building huge natural gas plants to power data centers. What could go wrong?
• The Trump Dictatorship Is Cracking Up
• Miami lands blue-chip quarterback for 2027 class